THE MODERN LIVING PEACE TRAIN™
Checking your passage…
One moment while your discovery opens.
Amyotrophic Lateral Sclerosis: essential context
Sources and review scope
These source notes explain the evidence consulted and its limits. Educational information does not replace individual medical care.
- ALS-FDA
- FDA: SOD1-ALS tofersen approval
Action; Effectiveness; accelerated approval; Safety information · Targeted accessible source text read; not a professional clinical appraisal or individualized recommendation.
Accessed 11 November 2026. 25 April 2023 approval context; no claim this is the newest evidence
- ALS-MFR
- Biogen: Qalsody indication and safety
Indication; Important safety information · Targeted accessible source text read; not a professional clinical appraisal or individualized recommendation.
Accessed 11 November 2026. Current manufacturer page read 11 November 2026; promotional source, targeted indication/safety only; not independent efficacy evidence
- ALS-NLM
- MedlinePlus: ALS
Summary; motor neurons; symptoms; diagnosis; treatment · Targeted accessible source text read; not a professional clinical appraisal or individualized recommendation.
Accessed 11 November 2026. Last updated 4 November 2026; targeted ALS-specific overview
- BREATH
- NHS: Shortness of breath
Immediate action and urgent advice; same-day retained source read · Targeted accessible source text read; not a professional clinical appraisal or individualized recommendation.
Accessed 11 November 2026. Reviewed 30 January 2024; next review 30 January 2027; same-day source check reused
- ALS-PI
- Qalsody (tofersen) prescribing information (PDF; revised April 2023)
§1 indication; §§5.1–5.3 warnings; §14 clinical studies, PDF pages 10–13 · Manufacturer-linked US prescribing information; targeted indication, serious warning and trial endpoint sections read independently for editorial/source accuracy. Not clinical appraisal or a complete regulatory-history audit.
Accessed 11 November 2026 through the manufacturer prescribing-information link. Label revision is April 2023; no claim of a new 2026 revision.